Dupixent® (dupilumab) smpc updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

Tarrytown, n.y. and paris, june 28, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european medicines agency will update the dupixent® (dupilumab) summary of product characteristics (smpc) adding long-term safety results for adults with moderate-to-severe atopic dermatitis based on a positive opinion by the committee for medicinal products for human use (chmp).
REGN Ratings Summary
REGN Quant Ranking